Home » Stocks » LPTX

Leap Therapeutics, Inc. (LPTX)

Stock Price: $2.21 USD -0.01 (-0.45%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $2.25 +0.04 (1.81%) Jan 15, 7:30 PM
Market Cap 132.44M
Revenue (ttm) 1.13M
Net Income (ttm) -38.87M
Shares Out 76.32M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.21
Previous Close $2.22
Change ($) -0.01
Change (%) -0.45%
Day's Open 2.21
Day's Range 2.14 - 2.24
Day's Volume 433,464
52-Week Range 1.17 - 2.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...

PRNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...

PRNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced t...

Seeking Alpha - 2 months ago

Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%...

Other stocks mentioned: CBD, CSCO, CVX, HON, IBM, INTC, JPM, UNH, VZ, WMT, YCBD
PRNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

PRNewsWire - 3 months ago

CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and...

PRNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.

PRNewsWire - 6 months ago

CAMBRIDGE, Mass., June 25, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

PRNewsWire - 6 months ago

CAMBRIDGE, Mass., June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...

Zacks Investment Research - 7 months ago

Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

PRNewsWire - 7 months ago

CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced ...

PRNewsWire - 7 months ago

CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

PRNewsWire - 8 months ago

CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported f...

Seeking Alpha - 10 months ago

Facing a de-listing from NASDAQ and forced to abandon its second clinical asset due to a cash crunch, Leap has rebounded somewhat on the back of a collaboration/financing deal.

Zacks Investment Research - 1 year ago

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

InvestorPlace - 1 year ago

Leap Therapeutics (LPTX) news for Friday has LPTX stock soaring following a major deal with BeiGene for its DKN-01 antibody. The post Leap Therapeutics News: LPTX Stock Takes a Massive 58% Le...

Zacks Investment Research - 1 year ago

Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.

Other stocks mentioned: ALDR, AMWD, COLM, DKS
Benzinga - 1 year ago

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

Other stocks mentioned: AMRN, AZN, JAZZ, LGND, LXRX, PHAS, RHHBY, SAGE, SBBP, SNY

About LPTX

Leap Therapeutics, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The compa... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Douglas E. Onsi J.D.
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
LPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is 5.10, which is an increase of 130.77% from the latest price.

Price Target
$5.10
(130.77% upside)
Analyst Consensus: Buy